ÂÜÀòÂÒÂ×

Zhengping Wang possesses extensive expertise in nonclinical development and clinical pharmacology, currently serving as SVP at REVOLUTION Medicines since March 2017, with prior roles including VP and Executive Director. Previous experience includes a Scientific Director position at Amgen focusing on preclinical ADME/PK and product life cycle management, as well as significant contributions at Onyx Pharmaceuticals, where roles spanned from Associate Director to Sr. Scientist, emphasizing lead optimization and regulatory submissions. Early career experience includes senior scientist roles at Proteolix and Cytokinetics, concentrating on bioanalysis and pharmaceutical science. Academic qualifications include a Ph.D. in LC-MS and Proteomics from the University of Alberta and an M.Sc. in Analytical Chemistry from Wuhan University.